Introduction
Drug resistance is the major reason for the ultimate failure of chemotherapy in the majority of human cancers. Certain types of cancer display intrinsic resistance to multiple chemotherapeutic drugs while many other cancers acquire multidrug resistance (MDR) during chemotherapy. MDR is frequently associated with the overexpression of P-glycoprotein (P-gp), a 170 kDa ATP-dependent transmembrane protein encoded by the MDR1 gene. P-gp resides in lipid raft microdomains (1) and is capable of pumping a number of structurally unrelated chemotherapy drugs and other compounds out of the cell.
The susceptibility of cancer cells to apoptosis induced by chemotherapeutic drugs depends on the balance between important pro-apoptotic and anti-apoptotic (survival) signals. ERK (extracellular-signal regulated kinases) and PI3K (phosphatidylinositol 3-kinase)/Akt kinase cascades play key roles in regulation of apoptotic responses and are known as important survival cell signaling pathways.
Many studies demonstrated the ability of modulators of protein phosphorylation/dephosphorylation to control the P-gp mediated multidrug resistance (2, 3) . It is known that P-gp can serve as a substrate for several protein kinases, such as protein kinase C (PKC), protein kinase A (PKA), CKII, P-gp specific kinase, but the functional significance of its phosphorylation is not yet clear and some reports indicate that certain protein kinase blockers inhibit drug transport by mechanism independent of P-gp phosphorylation (4, 5) . However, in several cancer cells a parallel expression of P-gp and activation and/or expression of mitogen-activated protein kinases (MAPKs), PKC, Akt kinase was found. Moreover, these protein kinase pathways have been reported to modulate the expression or activity of P-gp in some multidrug resistant cell lines (6) (7) (8) . In particular, it has been shown that the reversal of the MDR phenotype can probably occur by the suppression of P-gp expression via the inhibition of the PI3K/Akt/NF-κB signaling pathway (9) .
AKT, a serine/threonine protein kinase and a key downstream mediator of the phosphatidylinositol 3-kinase pathway, has been well studied for its role in cell growth, survival, migration, and differentiation both in physiological and pathological conditions. Three forms of AKT (AKT1, AKT2, and AKT3) exist in mammalian cells. Whereas they are known to share common substrates and functions, their specific role and task is still an intriguing and challenging question (10) .
Many cellular proteins are involved in regulating apoptosis, including members of the tumor necrosis factor (TNF) receptor superfamily of death receptors such as TNF-· receptor 1, Fas, and the tumor necrosis factor related apoptosis-inducing ligand (TRAIL) receptors DR4 and DR5 (11) . When productively bound by their respective ligands (TNF-·, FasL, and TRAIL) on the cell surface, the death receptors trimerize and a caspasedependent apoptotic pathway is initiated (12) (13) (14) (15) . TRAIL binds to four membrane receptors including death receptor 4 (DR4, TRAIL-R1), KILLER/DR5 (TRAIL-R2, TRICK2), DcR1 (TRID, TRAIL-R3), DcR2 (TRUNDD or TRAIL-R4), and a soluble receptor, osteoprotegerin (OPG). Only DR4 and DR5 contain cytoplasmic death domains and mediate apoptosis upon binding to TRAIL in sensitive target cells (16) . In contrast, neither DcR1 nor DcR2, which contains a truncated cytoplasmic death domain, mediate apoptosis after binding to TRAIL; thus serving as decoy receptors to sequester TRAIL at the cell surface (16) . TRAIL is a very promising cytokine for anticancer therapy since cancer cells are more sensitive to its cytotoxic activity compared to normal cells. However, despite early promising results, recent studies have identified several TRAIL-resistant cancer cell lines (17) (18) (19) . Several lines of evidence support a role for P-gp in enhancing TRAILinduced apoptosis: in fact, TRAIL induced preferential apoptosis in P-gp-bearing cells selected for resistance to several anticancer agents, as well as in cells transfected with the MDR1 and overexpressing P-gp (20) .
Leukemia cell lines can develop resistance to TRAILinduced apoptosis, and this can be due to increased level of pAkt which is partly due to phosphorylation of PTEN (21) . In particular, the doxorubicin-treated human T-lymphoblastic leukemic CEM cell line is characterized by both expression of P-gp and high levels of Akt activation (22) (23) (24) and parental CEM cells are more resistant to TRAIL-induced apoptosis, compared with other human chronic myeloid leukemic cell lines (25) .
Although leukemia drug resistance has been defined by means of gene expression profiling, at a proteomic level data are controversial as to how signaling pathways are differentially activated and serve to control cell proliferation and drug resistance regulation. Given these premises, we decided to perform a comparative analysis of the endogenous phosphorylome in two isogenic variants of human T lymphoblastoid CEM cell line, one sensitive to drug-induced apoptosis, while the other, referred to as MDR-CEM, derived from the parental one by selection with vinblastine treatment, and displaying a cross-resistance to many other chemotherapeutic drugs (26, 27) . In order to compare the phosphorylation profile of multiple proteins, we utilized the high throughput reversephase protein array technology (RPPA). Our results indicate that the two subtypes MDR-CEM and CEM showed distinct pathway activation that are not obvious from previous gene expression studies. We also show that basal levels of phosphorylation of key signaling nodes may have diagnostic utility in predicting response to selective inhibitors of Akt pathway. In an attempt to assess Akt1 as a candidate for treatment of MDR malignancies, parental CEM leukemia cells and the isogenic MDR-CEM subline were screened for TRAIL responsiveness. The results presented here confirmed that TRAIL was completely ineffective on parental CEM cells, while triggered massive apoptosis in the MDR-counterpart. This pattern correlates with the opposite expression and activation trend of Akt1 in MDR-CEM cells. Furthermore, in these cells TRAIL treatment affects Akt1 protein level, rather than its activation, through a degradation mechanism. This interesting result prompted us to analyze deeper the effect triggered by TRAIL on the above phosphorylation pathways.
Materials and methods
Materials. Doxorubicin chloridrate was from Pharma Italia; MG-132, anti-actin and cycloheximide were from Sigma (St. Louis, MO, USA); the broad caspase inhibitor Z-Vad fmk and anti-MDR were from Calbiochem (La Jolla, CA, USA). TRAIL was from PeproTech (London, UK). Anti-PHLPP was from Bethyl Lab. (Montgomery, TX, USA).
The following antibodies were used: anti-Akt1, anti-Akt2, anti-NF-κB, anti-PARP, all from Santa Cruz Biotechnology, CA; anti-phospho-GSK3ß, antiGSK3ß, anti-phosphoAkt(Ser473), anti-phospho-Akt(Thr308), anti-phospho-PDK1, anti-phospho-PTEN, anti-PTEN, anti-phospho-mTOR, anti-mTOR and anti-phospho-PRAS40 from Cell Signaling Technology (Beverly, MA USA). Horseradish peroxidaseconjugated (HRP) secondary antibodies as well as chemiluminescence (ECL) reagents were from Amersham Pharmacia Biotech (Piscataway, NJ, USA). All electrophoresis reagents, nitrocellulose and protein assay kits were from Bio-Rad (Hercules, CA, USA). All other chemicals were of the highest quality available.
Cell culture and treatments. The human T-lymphoblastic leukemic CEM cell line was maintained in RPMI-1640 medium (EuroClone Ltd., UK) supplemented with 10% fetal bovine serum (FBS, EuroClone Ltd., UK). The multidrug resistant subline, MDR-CEM, was obtained by continuous exposure to doxorubicin, as described by Cenni et al (28) and maintained as parental-U2OS. Cells were treated with 0.5-1 μg/ml TRAIL or vehicle alone and used for experiments. Where indicated, cells were pre-treated with 20 μM cycloheximide, 10 μM MG-132 or 20 μM Z-Vad fmk.
Preparation of cell extracts. CEM cells were extracted by addition of RIPA buffer (20 mM Tris-Cl, pH 7.0, 1% NP-40, 150 mM NaCl, 10% glycerol, 10 mM EDTA, 20 mM NaF, 5 mM sodium pyrophosphate, 1 mM Na 3 VO 4 , and freshly added Sigma-Aldrich Protease Inhibitor Cocktail) at 4˚C for 10 min. Lysates were cleared by centrifugation and used for immunoprecipitation experiments, as described below. Total lysate (50 μl) was boiled in SDS sample buffer, resolved, and immunoblotted with the indicated antibodies. In brief, samples were loaded onto an SDS-polyacrylamide gel, blotted on Immobilon-P membranes (Millipore, MA), and processed by Western blotting with the indicated antibody, detected by Supersignal substrate chemiluminescence detection kit (Pierce, UK). Quantitation of the signal was obtained by chemiluminescence detection on a Kodak Image Station 440CF and analysis with Kodak 1D Image software.
Flow cytometry. The expression of TRAIL receptors and P-gp was analyzed by indirect staining using mouse anti-human TRAIL-R1, TRAIL-R2 (Alexis, Lausen, Switzerland) and mouse anti-human P-gp (BD Pharmingen) as specified by Milani et al (29) followed by phycoerythrin-conjugated rabbit anti-mouse IgG (Sigma). Non-specific fluorescence was assessed by using normal mouse IgG followed by the second antibody as described above. Analyses were performed with a FACScan flow cytometer and Lysis II software (both from Becton-Dickinson, San Jose, CA, USA).
Reverse-phase protein arrays. Cells were grown in standard media and 10% fetal bovine serum until they reached 60-80% confluence and then lysed directly in plates in buffer consisting of a 2.5% solution of 2-mercaptoethanol in loading buffer/T-PER plus phosphatase and protease inhibitors. All samples were diluted to a final concentration of 0.5 mg/ml and then 30 μl of each sample, arrayed in a series of 6-fold dilutions, was printed in duplicate on slides. Lysates derived from HeLa cells or HeLa cells treated with pervanadate were also printed on each slide as low and high phosphorylation controls, respectively. The slides were then subjected to immunostaining with a panel of 90 commercially available antibodies primarily directed against specific phosphorylated or cleaved proteins, including PI-3K/Akt, ERK/MAPK, PKCs and caspase-dependent apoptosis. Each of these antibodies had previously undergone extensive validation for both phosphorylation and protein specificity using single band detection at the appropriate MW by Western blotting. To estimate the total protein amount, selected arrays were stained with Sypro Ruby protein blot stain (Molecular Probes, Eugene, OR, USA) and visualized on a Fluorchemk imaging system (Alpha Innotech, San Leandro, CA, USA). Slides were stained on an automated slide stainer (Dako, Carpinteria, CA, USA) using a biotin-linked peroxidase catalyzed signal amplification. Finally, the primary antibodies at concentrations ranging from 1:50 to 1:1000 were applied for 30 min followed by the secondary link antibody for 30 min (concentration 1:10 for anti-mouse antibodies and 1:5000 for anti-rabbit antibodies). To allow normalization of total protein on printed arrays, one to two slides in each print run were stained with Sypro Ruby protein blot stain (Invitrogen) and the value of these stained arrays used for normalization of all end-point values.
The intensity value for each end point was determined by identifying spots for each duplicate dilution curve for each sample that were within the linear dynamic range of the staining after background subtraction with each spot (within slide local background and also against a slide stained with secondary antibody only). Single intensity values were obtained by multiplying each spot in the linear range by its dilution factor and averaging candidate linear points. Finally, each value was normalized relative to the total protein intensity value for that sample derived from the Sypro Ruby-stained slide.
Statistical analysis. Statistical analysis was performed with Student's unpaired t-test. Results are the mean of at least three independent experiments. Differences were considered significant at P<0.05.
Results

P-gp expression in CEM cells.
The multidrug resistant clone, herein called MDR-CEM, has been selected by continuous exposure of CEM cells to doxorubicin and characterized (27) . To investigate the surface expression of P-gp, parental-and MDR-CEM cells were fixed and incubated with a FITCconjugated anti-P-gp antibody and subjected to flow cytometric analysis (Fig. 1A) . The results show that, while parental CEM is completely P-gp deficient, MDR-CEM cells possess considerable levels of the membrane transporter, as confirmed also by Western blot analysis (Fig. 1B) . on a nitrocellulose covered glass substratum, allowing subsequent immunodetection both of the total levels and of phosphorylated, or activated, signaling proteins. We profiled protein lysates from parental-and MDR-CEM cells with a panel of 90 antibodies recognizing primarily phosphorylated epitopes for ERK, PCK and Akt pathways ( Fig. 2A) , already validated by the lab of Liotta et al (30) (31) (32) . It is interesting to note that several endpoints are differentially expressed or activated. In particular, we address here the Akt pathway phosphorylome, and its relation to the MDR-phenotype. Fig. 3A shows that Akt pathway activation seems to play a key role in determining the different somatic features of MDR-CEM cells. In particular, given that parental-CEM cells express higher levels of the Akt1 protein, the unexpected finding that Akt phosphorylation at S473 is higher in MDR-CEM, while phosphorylation at T308 is comparable in the two cell clones, suggested that Akt1 phosphorylation at S473 may represent an important cue of MDR in CEM cells, as observed before by us and others in different cell types (28) . Since Akt activity is finely tuned by well known kinases and phosphatases, we analyzed the phosphorylation profile of upstream and downstream Akt regulatory molecules in the two cell types.
RPPA analysis of the phosphorylation pathways activated in
In good agreement with the above result, we can observe that PTEN protein level, as well as phosphorylation, is almost undetectable in MDR-CEM cells (Fig. 3B) . Likewise, the very low content of the pS473 protein phosphatase PHLPP in MDR-CEM cells, with respect to S-CEM, substantiate the above result, accounting for the much higher Akt kinase activity/phosphorylation in these cells (Fig. 4) . On the other hand, the activity of the S473-kinase, mTORC2 (33) , is clearly augmented in MDR-CEM cells, as detected by antipS2481, contributing to explain the discrepancy between the two subclones.
The proline-rich Akt substrate of 40 kDa (PRAS40) was identified as a novel mTOR binding partner that mediates Akt signals to mTOR and is therefore regarded as an important regulator of insulin sensitivity of the Akt-mTOR pathway. Upon phosphorylation by Akt, indeed, PRAS40 binds to 14-3-3, thus relieving its inhibition of mTORC1 (33) . Our data provided evidence that PRAS40 is heavily phosphorylated in multidrug resistant cells, compared to parental cells (Fig. 3B) .
As far as the Akt-downstream pathway, we investigated the epitope-specific phosphorylation of well known substrates such as GSK3ß (glycogen synthase kinase 3ß), which directly phosphorylates and thus inactivates glycogen synthase, and the transcription factor NF-κB, which mediates at least to some extent Akt-promoted cell survival. Fig. 3B clearly shows that phosphorylation of p65 at Ser536 is doubled in MDR-CEM, indicating that NF-κB transcriptional activity is much more sustained in these cells. Conversely, GSK3ß phosphorylation is similar, if not a little weaker in MDR cells than in sensitive cells. However, this result can be easily explained by the observation that the amount of total GSK3ß is more than halved in MDR-CEM cells, therefore the phosphorylation decreased accordingly (not shown).
In order to serve as both a diagnostic and a therapeutic guide, the correlation of these results with biological and clinical information has to be confirmed by Western blot analysis.
Western blot analysis of the Akt pathway activated in MDR-CEM cells.
Most importantly, we found a good concordance between the phosphorylation profile determined by Western blot analysis and that obtained by RPPA analysis (Fig. 4) by RPPA in this model is reproducible. Furthermore, to deeper investigate the Akt regulation in MDR-CEM cells, we analyzed by Western blot analysis (Fig. 4) the expression of several effectors of the Akt pathway.
As we have pointed out above, the levels of PH domain leucine-rich repeat protein phosphatase (PHLPP), that specifically dephosphorylates the hydrophobic motif of Akt (Ser473 in Akt1) triggering apoptosis and suppressing tumor growth (35) , are markedly reduced in MDR-CEM cells that have elevated Akt Ser473 phosphorylation.
The intensity of GSK is much higher in parental CEM cells, indicating that the phosphorylation pattern observed with RPPA analysis is due to the protein expression (Fig. 4) . On the other hand, mTOR is equally present in both cell lines (Fig. 3) , while Fig. 2B shows an increased mTOR phosphorylation in MDR-CEM cells.
Analysis of TRAIL sensitivity and TRAIL-R1 and -R2 expression in parental-and multi-drug resistant CEM cells.
Hyperactivation of Akt tips the balance of cells into survival pathways and is often correlated with tumor progression.
Our current study demonstrated that the acquired resistance to doxorubicin was partly due to activation of Akt1 and inactivation of PTEN and PLHPP.
We therefore investigated the response of both parental and resistant CEM cells to TRAIL, a member of the tumor necrosis factor (TNF) family of cytokines that is considered to induce death of cancer cells but not normal cells, preferentially causes apoptosis through the same mechanisms, such as increased level of pAkt and loss of PTEN activity (21) . Cells were treated with doses of TRAIL ≤1 μg/ml for 16 h, collected, and subjected to Western blotting or PI staining and FACS analysis.
As assessed by WB detection of cleaved poly(ADP-ribose) polymerase (PARP) (Fig. 5A) , while untreated cells have similar PARP levels, only MDR-CEM cells exhibit a marked responsiveness to TRAIL-induced apoptosis. However, Fig. 5B shows the profile of TRAIL receptors obtained by FACS: the parental-and MDR-CEM cells express comparable levels of TRAIL-R1 and -R2, hampering any correlation with resistance or sensitivity to TRAIL-induced apoptosis and suggesting significant clinical implications for the use of TRAIL in treating neoplasms that have failed chemotherapy. Akt1 expression, unlike the activity, leads to TRAIL responsiveness of MDR-CEM cells. Since both parental-and MDR-CEM cells express high levels of active TRAIL receptors, but TRAIL effectiveness is limited to MDR-CEM, we then investigated the Akt-related post-receptor intracellular mechanisms of the two cell types. To begin with, we examined the balance between total and phosphorylated Akt. RPPA test indicates that Akt phosphorylation at T308 and S473 decreases in MDR-CEM in response to the presence of TRAIL (Figs. 2B and 5C ). Then the amount of total and activated Akt was analyzed by Western blotting followed by densitometric scanning, yielding a remarkable difference between parentaland MDR-CEM cells (Fig. 5A ). In fact, as shown in Fig. 4 , parental-CEM cells express much more Akt1 than their MDR counterpart, though considerably less active. Indeed our data show that TRAIL treatment causes a dramatic reduction of Akt1 protein level, and therefore of the protein phosphorylation (Fig. 5A) , suggesting that TRAIL responsiveness is associated to Akt1 presence in MDR-CEM cells.
In particular, TRAIL treatment also modulates Akt key effectors: in particular Fig. 5D shows that phosphorylation of PRAS40, the mTOR binding partner that mediates Akt signals to mTOR, is abrogated, confirming the link between TRAIL responsiveness and Akt/mTOR pathway. It is interesting to note that TRAIL treatment results in a negative modulation of the whole Akt pathway, as shown by the further decrease observed in the case of pPDK1, pPTEN and pGSK (Fig. 5C) . The above result can be ascribed to the dramatic degree of apoptosis induced by TRAIL in this cell subclone.
Apoptosis induction by TRAIL is shown by Fig. 5D : the increase of cleaved caspases 6 and 9 clearly indicates that TRAIL treatment drives MDR-CEM cells to caspase-mediated cell death. Moreover, Bad phosphorylation, that is important in the prevention of apoptosis, is higher in untreated MDR-CEM cells.
Akt1 modulation in multi-drug resistant CEM cells exposed to TRAIL. We then sought to investigate whether the modulation of Akt1 content in MDR-CEM cells results from a reduced synthesis or an increased degradation of Akt1. As shown in Figs. 5A and 6, the long-term TRAIL stimulation strongly reduces expression of endogenous Akt1, while the phosphorylation level seems not to be crucial.
Although Akt level is quite stable in MDR-CEM cells after treatment with the inhibitor of protein biosynthesis Cycloheximide, co-treatment with TRAIL triggers Akt fast degradation. The treatment with the broad proteasome inhibitor MG-132 (MG) does not abrogate TRAIL-dependent Akt1 degradation, as shown in Fig. 6 . The reduced content of endogenous Akt1 is most likely due to the activation of apical caspases, leading to Akt1 degradation, as this reduction was reversed by pre-treatment with the broad caspase inhibitor Z-Vad (Fig. 6 ).
Discussion
Analysis of the genome provides important information on the somatic genetic changes existing in the tissue; however, it is the proteins that do the work of the cell. Diseases such as cancer are caused by derangements in cellular protein molecular networks and cell signaling pathways. These pathways contain a large and growing collection of drug targets, governing cellular survival, proliferation, invasion, and cell death. Proteomics has the potential to provide answers in cancer pathogenesis and to direct targeted therapy through the comprehensive analysis of protein expression levels and activation status. The realization of this potential requires the development of new, rapid, high-throughput technologies for performing protein arrays on patient samples, as well as novel analytical techniques to interpret them. The clinical utility of reverse-phase protein microarrays (RPPA) lies in its ability to generate a functional map of known cell signaling networks or pathways for an individual patient (36) .
In this study we used RPPA analysis to investigate the signaling pathway characteristic of a human leukemia cell line resistant to doxorubicin treatment (MDR-CEM). The drug efflux activity of P-gp represents a common mechanism that tumor cells use to escape from death induced by different chemotherapeutics agents (6) . It has been found that modulators of some protein kinase pathways, especially MAPK (ERK, p38-MAPK), can influence drug transport activity of P-gp in multidrug resistant L1210/VCR, a mouse leukemic cell line (6, 37) . Here we found that the Akt pathway is linked to multidrug resistance of CEM cells. In fact, one of the most effective antiapoptotic survival pathway in mammals is constituted of phosphoinositide 3-kinase (PI3K)/Akt (38, 39) . The active, phopshorylated form of Akt (pAkt) promotes cell proliferation and survival by phosphorylating downstream molecules that regulate cell cycle and apoptosis (40) . We demonstrate that the activated form of the isoform 1 of Akt (Akt1), rather than the protein content, is a typical marker of multidrug resistance. In fact, Akt1 protein level is lower in MDR-CEM cells than in parental CEM cells, indicating that the only genome analysis of leukemic patient could be misleading.
RPPA and Western blot analysis data then confirmed that S473 phosphorylation of Akt1 and the upstream and downstream transduction pathway play a pivotal role in modulating MDR-CEM survival. It has been published that there is molecular proximity between P-gp, and DR4, DR5, and DcR1 (receptors of TRAIL), then it is plausible that crosstalk between P-gp and TRAIL receptors may take place in lipid raft microdomains (20) . Moreover, recent data clearly showed that lipid raft microdomains are closed chambers in which death receptors, including DR4 and DR5, as well as procaspase-8, procaspase-10, FADD, and Bid reside, and that death-mediated apoptotic signaling mechanisms are dependent upon lipid rafts (41) (42) (43) . The TNF-related apoptosis-inducing ligand, TRAIL, has been shown to selectively kill tumor cells. This property has made TRAIL and agonistic antibodies against its death inducing receptors (TRAIL-R1 and TRAIL-R2) a most promising novel biotherapeutic agent for cancer therapy. The TRAIL death receptor-mediated 'extrinsic' pathway and the 'intrinsic' pathway, which is controlled by the interaction of members of the Bcl-2 family, interact with each other in the decision about life or death of a cell. Apoptotic and non-apoptotic signaling is influenced by the NF-κB, PKB/Akt and the MAPK signaling pathways (44) . Further understanding of the molecular mechanisms of TRAIL-induced apoptosis in drug-sensitive and -resistant cells should provide insight and approaches useful for the development of more effective therapeutic strategies to eliminate cancer cells.
An analysis of the post-receptor events showed that TRAIL responsiveness correlates with a reduced expression of endogenous Akt1. Furthermore, our results confirm the observations indicating that the upregulation of P-gp in neoplasms that have failed chemotherapy can be exploited as an Achilles heel that sensitizes the cancer cells to TRAIL therapy.
